Skip to main content

Advertisement

SpringerLink
Log in

LncRNA MBLN1-AS1 inhibits the progression of retinoblastoma through targeting miR-338-5p-Wnt/β-catenin signaling pathway

  • Original Research Paper
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Objective and design

Retinoblastoma is the most common primary intraocular malignancy of childhood, which brings a heavy burden to the countries across the world, especially the developing countries. It has been shown that lncRNA muscleblind-like 1 antisense RNA 1 (MBNL1-AS1) exerts anti-tumor effects in various cancers, including bladder cancer, papillary thyroid cancer, and retinoblastoma. In the present study, we hypothesized that MBNL1-AS1 might play a protective role against retinoblastoma.

Methods

The expression of MBNL1-AS1 and its potential target miR-338-5p were evaluated in retinoblastoma cell line by real-time quantitative PCR and western blot. The involvement of MBNL1-AS1-miR-338-5p in the cell proliferation was evaluated by cell counting kit-8 (CCK8), and colony formation assay. The cell migration was evaluated by Transwell assay in Y79 cells, a retinoblastoma cell line. The involvement of MBNL1-AS1-miR-338-5p in tumor formation was also evaluated in mice.

Results

It was found that MBNL1-AS1 overexpression inhibited proliferation and migration in Y79 cells. In addition, the inhibitory effects of MBNL1-AS1 on Y79 cells were significantly reversed in the presence of miR-338-5p mimics, and MBNL1-AS1 overexpression significantly decreased miR-338-5p level in Y79 cells. Furthermore, MBNL1-AS1 overexpression significantly inhibited Wnt/β-catenin signaling pathway, and this inhibitory effect was almost lost in the presence of miR-338-5p mimics. Finally, our in vivo study showed that MBNL1-AS1 overexpression significantly inhibited Y79-induced retinoblastoma in mice, and this inhibitory effect was lost in the presence of miR-338-5p mimics.

Conclusion

Our study shows that MBNL1-AS1 exerts its anti-tumor effect by targeting miR-338-5p, thereby inactivating wnt/β-catenin signaling pathway in retinoblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Hao F, Mou Y, Zhang L, Wang S, Yang Y. LncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma. Biosci Rep. 2018;38(3):BSR20180384.

    Article  CAS  Google Scholar 

  2. Fabian ID, Onadim Z, Karaa E, et al. The management of retinoblastoma. Oncogene. 2018;37(12):1551–60.

    Article  CAS  Google Scholar 

  3. Rao R, Honavar SG. Retinoblastoma. Indian J Pediatr. 2017;84(12):937–44.

    Article  Google Scholar 

  4. Wei X, Wang B, Wang Q, et al. MiR-362-5p, which is regulated by long non-coding RNA MBNL1-AS1, promotes the cell proliferation and tumor growth of bladder cancer by targeting QKI. Front Pharmacol. 2020;11:164.

    Article  CAS  Google Scholar 

  5. Fu XM, Guo W, Li N, et al. The expression and function of long noncoding RNA lncRNA-ATB in papillary thyroid cancer. Eur Rev Med Pharmacol Sci. 2017;21(14):3239–46.

    PubMed  Google Scholar 

  6. Yang G, Fu Y, Lu X, Wang M, Dong H, Li Q. LncRNA HOTAIR/miR-613/c-met axis modulated epithelial-mesenchymal transition of retinoblastoma cells. J Cell Mol Med. 2018;22(10):5083–96.

    Article  CAS  Google Scholar 

  7. Wei X, Yang X, Wang B, et al. LncRNA MBNL1-AS1 represses cell proliferation and enhances cell apoptosis via targeting miR-135a-5p/PHLPP2/FOXO1 axis in bladder cancer. Cancer Med. 2020;9(2):724–36.

    Article  CAS  Google Scholar 

  8. Zhu K, Wang Y, Liu L, Li S, Yu W. Long non-coding RNA MBNL1-AS1 regulates proliferation, migration, and invasion of cancer stem cells in colon cancer by interacting with MYL9 via sponging microRNA-412-3p. Clin Res Hepatol Gastroenterol. 2020;44(1):101–14.

    Article  CAS  Google Scholar 

  9. Wang JH, Zhang L, Huang ST, et al. Expression and prognostic significance of MYL9 in esophageal squamous cell carcinoma. PLoS ONE. 2017;12(4):e0175280.

    Article  Google Scholar 

  10. Li P, Xing W, Xu J, et al. microRNA-301b-3p downregulation underlies a novel inhibitory role of long non-coding RNA MBNL1-AS1 in non-small cell lung cancer. Stem Cell Res Ther. 2019;10(1):144.

    Article  Google Scholar 

  11. Zhou P, Li X. Serum miR-338-5p has potential for use as a tumor marker for retinoblastoma. Oncol Lett. 2019;18(1):307–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Gao Y, Lu X. Decreased expression of MEG3 contributes to retinoblastoma progression and affects retinoblastoma cell growth by regulating the activity of Wnt/beta-catenin pathway. Tumour Biol. 2016;37(2):1461–9.

    Article  CAS  Google Scholar 

  13. Wu T, Wang LN, Tang DR, Sun FY. SOST silencing promotes proliferation and invasion and reduces apoptosis of retinoblastoma cells by activating Wnt/beta-catenin signaling pathway. Gene Ther. 2017;24(7):399–407.

    Article  CAS  Google Scholar 

  14. Yang M, Li Y, Wei W. MicroRNA-188-5p promotes epithelial-mesenchymal transition by targeting ID4 through Wnt/betacatenin signaling in retinoblastoma. Onco Targets Ther. 2019;12:10251–62.

    Article  CAS  Google Scholar 

  15. Oshikawa M, Tsutsui C, Ikegami T, et al. Full-length transcriptome analysis of human retina-derived cell lines ARPE-19 and Y79 using the vector-capping method. Invest Ophthalmol Vis Sci. 2011;52(9):6662–70.

    Article  CAS  Google Scholar 

  16. Liu Y, Hu H, Liang M, et al. Regulated differentiation of WERI-Rb-1 cells into retinal neuron-like cells. Int J Mol Med. 2017;40(4):1172–84.

    Article  CAS  Google Scholar 

  17. Xu L, Li W, Shi Q, et al. MicroRNA936 inhibits the malignant phenotype of retinoblastoma by directly targeting HDAC9 and deactivating the PI3K/AKT pathway. Oncol Rep. 2020;43(2):635–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Ju C, Zhou R, Sun J, et al. LncRNA SNHG5 promotes the progression of osteosarcoma by sponging the miR-212-3p/SGK3 axis. Cancer Cell Int. 2018;18:141.

    Article  Google Scholar 

  19. Li J, Guo Y, Duan L, et al. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. Oncotarget. 2017;8(20):33694–703.

    Article  Google Scholar 

  20. Wu XZ, Cui HP, Lv HJ, Feng L. Knockdown of lncRNA PVT1 inhibits retinoblastoma progression by sponging miR-488–3p. Biomed Pharmacother. 2019;112:108627.

    Article  CAS  Google Scholar 

  21. Huo Y, Wang Q, Liu Y, et al. A temperature-sensitive phase-change hydrogel of topotecan achieves a long-term sustained antitumor effect on retinoblastoma cells. Onco Targets Ther. 2019;12:6069–82.

    Article  CAS  Google Scholar 

  22. Aldred SF, Collins P, Trinklein N. Identifying targets of human micrornas with the LightSwitch Luciferase Assay System using 3’UTR-reporter constructs and a microRNA mimic in adherent cells. J Vis Exp. 2011; (55).

  23. Song B, Lin HX, Dong LL, Ma JJ, Jiang ZG. MicroRNA-338 inhibits proliferation, migration, and invasion of gastric cancer cells by the Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(5):1290–6.

    CAS  PubMed  Google Scholar 

  24. Zhang T, Liu W, Zeng XC, et al. Down-regulation of microRNA-338–3p promoted angiogenesis in hepatocellular carcinoma. Biomed Pharmacother. 2016;84:583–91.

    Article  CAS  Google Scholar 

Download references

Funding

Not applicable.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, The First Affiliated Hospital of Gannan Medical University, No. 23 Qingnian Road, Zhanggong District, Ganzhou, 341000, Jiangxi Province, China

    Lei Xu, Aidong Tang & Wanrong Liu

  2. The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, Jiangxi Province, China

    Shenyu Zhu

Authors
  1. Lei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shenyu Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Aidong Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wanrong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LX and WRL contributed to the conception and design of the study; LX, SYZ and ADT performed the experiments and collected the data; SYZ and ADT performed the statistical analysis; LX and SYZ completed data interpretation; LX and WRL wrote the manuscript and revised manuscript; All authors contributed to reading and revising the manuscript and approved the submitted version.

Corresponding author

Correspondence to Wanrong Liu.

Ethics declarations

Conflict of interest

There are no conflict of interest in this investigation.

Additional information

Responsible Editor: John Di Battista.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, L., Zhu, S., Tang, A. et al. LncRNA MBLN1-AS1 inhibits the progression of retinoblastoma through targeting miR-338-5p-Wnt/β-catenin signaling pathway. Inflamm. Res. 70, 217–227 (2021). https://doi.org/10.1007/s00011-020-01432-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-020-01432-z

Keywords

Search

Navigation